Steven D. Harr, M.D. is a co-founder of Sana and has served as our President and Chief Executive Officer since September 2018 and as a member of our Board since October 2018. Prior to Sana, Dr. Harr served as Chief Financial Officer and Head of Corporate Development at Juno Therapeutics, Inc. from April 2014 until its acquisition by Celgene Corporation in March 2018. At Juno, Dr. Harr was responsible for the overall financial and operational strategy of the company. Prior to Juno, Dr. Harr was Managing Director and Head of Biotechnology Investment Banking at Morgan Stanley, a public multinational investment bank and financial services company, from May 2010 until April 2014, and prior to his investment banking role was the Lead Biotech Research Analyst and Co-head of Global Healthcare Research at Morgan Stanley. Dr. Harr previously served as a member of the boards of directors of Loxo Oncology, Inc., which was a public biopharmaceutical company during Dr. Harr’s service as a director, until its acquisition by Eli Lilly and Company in early 2019, and JW (Cayman) Therapeutics Co. Ltd, a public cell therapy company in China that he co-founded. Dr. Harr was a resident in internal medicine at the University of California, San Francisco and performed research at Harvard Medical School and Massachusetts General Hospital. Dr. Harr received his M.D. from the Johns Hopkins University School of Medicine and his B.A. in Economics from the College of the Holy Cross.